As I have said the well is dry in the Covid space in terms of momentum because of the absence of real news. Investors will no longer invest on anything other than concrete. Applications, new trials, hopeful expectations, strategy, or any news other than real news will not fly in the Covid therapeutic lotto race.
Nader is certainly no exception as he leads the field in most all time non news PR’s. That translates to a big yawn from the broad market and a big jab to the gut for loyal investors.
As has been articulated consistently in many posts this morning the EUA in the UK is a gamble to say the least. Best case outcome for the Fast Track Application is the granting of FT by the UK but that doesn’t mean approval as it will require a trial within the UK - that’s the way they they roll. How do you think that will impact SP? It means more time until enough evidence can be accumulated to determine approval. Investors are worn out w empty promises and hope and will not risk their capital on anything other than results that translate to increased valuation.
One further piece of information to consider that adds brevity to the odds for EUA is the disappearance of two catalysts that Nader promoted prior to the MM topline report.
1- “Five Big Pharma’s waiting in the wings for the topline report”. Where are the big shots? It now seems obvious that their KOL’s looked at the report and came to the conclusion that there wasn’t enough there to gain EUA in the US or any other market for that matter. If they thought otherwise they would have jumped at a partnership as an EUA would mean instant revenue and global exposure. That is the biggest tell IMO - once again no interest by BP. Our achilles heal w Nader as our mouthpiece.
2- “National media outlets ready and primed to tell the story”. I was told by a source that the day the topline report came out Nader was trying to get on CNN. Apparently there was some type of arrangement that fell as flat as the topline report did on the market. Obviously the whole plan blew up. No BP interest and no media blitz.
Without EUA in US, UK, or EU the SP is going to trend down until the moment of truth which is the S/C interim readout. That by my calculations is realistically 60 days out. If you disagree w the 60 days do your own math and lay your bets down as you see fit. Being able to accurately determine the S/C interim readout date is now the most important investment information to be predicted other than the results themselves. The point is that is a significant stretch of time that will apply downward pressure to the SP in the absence of MM EUA.
I’m convinced that S/C Trial is the holy grail for Leronlimab and CYDY. This is a trial that is designed for success that will IMO exploit Leronlimab’s therapeutic benefits just as Dr. Bruce Patterson has stated numerous times.
In hindsight the most critical error was making the decision to take on the MM Trial. That wasn’t our strength as it was uncharted territory and understood industry wide to be a difficult patient population to show statistically significant results. Hey we hit a secondary endpoint which is better than anyone else, unfortunately it may not deliver the result we were hoping for.
GLTAL’s - this story has a long ways to go.
AI
